Corvus Pharmaceuticals Inc
CRVS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.04B
Close$
$0.05
99.6% downside
Current Fair Value
99.6% downsideOvervalued by 99.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.04 Billion |
|---|---|
| Enterprise Value | $1.00 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.19 |
| Beta | 0.94 |
| Outstanding Shares | 89,996,728 |
Return
| Return on Equity | -18.35% |
|---|---|
| Return on Assets | -17.44% |
| Return on Invested Capital | -20.06% |
Valuation & Multiples
| P/E Ratio | -25.29 |
|---|---|
| PEG | 13.3 |
| Price to Sales | - |
| Price to Book Ratio | 5.8 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -20.76 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3324▼ 88.35% |
|---|---|
| Total Calls | 1,295,570▲ 158.29% |
| Total Puts | 430,700▼ 29.38% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 88.61%▲ 32.26% |
|---|---|
| Total Invested | $1.02B▲ 184.64% |
| Investors Holding | 173▲ 40.00% |
ESG Score
No data
About Corvus Pharmaceuticals Inc
CEO: Richard Miller